DAVIS EUGENE I purchased $126K of WW

DAVIS EUGENE I purchased 10,000 shares of WW INTERNATIONAL, INC. (WW) at $12.63 ($0.13M total) on 2026-05-22.

Original reporting
SEC EDGAR · DAVIS EUGENE I
Published May 27, 2026, 8:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 8:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$WW
Neutral
low confidence
Mentioned
$WW
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WWNeutralLow
01

Why it matters

This disclosure may slightly improve sentiment among short-term traders, but it does not introduce new operating or financial information.

02

Market read

Treat as a low-signal sentiment datapoint unless corroborated by subsequent filings or fundamental news.

03

What to watch

No 10b5-1 plan is cited, but the article provides no rationale for the buy, prior trading history, or whether the director’s holdings are material relative to total ownership.

Relevance 6/10Timing: Immediate (filed 2026-05-27) but likely more sentiment than catalyst.

Background

The article is an SEC Form 4 insider transaction: director Eugene I. Davis purchased WW shares in an open-market transaction.

Company-level read

Ticker impact

$WWNeutralLow confidence
Context

WW International disclosed a director open-market purchase of 10,000 shares for about $126.3K via SEC Form 4.

Expected impact

Limited near-term impact; any reaction is likely short-lived unless followed by additional buying or operational news.

Evidence & confidence

The filing is an ownership-change disclosure only (no earnings, guidance, deal, or regulatory update). The absence of a 10b5-1 plan and the director’s purchase may support sentiment, but size and lack of context reduce predictive power.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

Insider purchases on Form 4 can reflect liquidity needs, diversification, or routine compensation-related behavior rather than a strong forward view.

Key entities

  • WW International, Inc.

    Subject of the Form 4 insider purchase disclosed on 2026-05-27.

  • DAVIS EUGENE I

    Director who reported an open-market purchase of 10,000 WW shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WWMedAI 8/10

What WW International (WW) Said on Its Q3 Earnings Call

WW International reported Q3 earnings, highlighting a 40% YoY increase in clinical subscribers to 174,000, though down from 197,000 in Q2. Behavioral subscription revenue fell 22% to $113.9M, while clinical revenue rose 48% to $38M. Adjusted gross margin reached 74.6%, and marketing expenses declined. The company narrowed its 2026 revenue guidance to $625M-$630M and adjusted EBITDA to $110M-$115M. Cash increased to $126.4M, and debt was reduced by 70%.

$WWMedAI 8/10

WW International Inc (WW) (Q3 2026) Earnings Call Highlights: Clinical Revenue Surges 48%

WW International reported Q3 2026 revenue of $152.9M, down 11% YoY, with behavioral subscription revenue dropping 22%. Clinical revenue surged 48%, but clinical subscribers declined sequentially. Full-year revenue guidance was narrowed to $625-$630M. Core+ subscribers grew 16% YoY, driven by GLP-1 program adoption and virtual experiences. The company expects flat gross margins at ~74% despite clinical mix growth.

$WWMed

WW International, Inc. Q3 2026 Earnings Call Summary

WW International reported Q3 2026 earnings, highlighting a strategic shift to higher-value tiers (Core+ and Med+) generating 50% of revenue. Clinical revenue grew 48% YoY, driven by Med+ and GLP-1 Success Program. Core+ saw subscriber growth for four consecutive quarters. The company expects sustainable growth in 2027, with clinical revenues projected to reach 25% of total revenue. Debt reduced by 70% since 2025, and net income turned positive.